Conor Corio
This article was originally published in The Gray Sheet
Executive Summary
Firm announces initiation of the 150-patient RAPID trial to evaluate its Corio pimecrolius-eluting stent in Brazil and Europe on May 11. The drug - licensed from Novartis in March - prevents inflammation, which is believed to be a primary cause of restenosis, according to Conor Medsystems. Data from the study will be compared to historical controls from the firm's EuroSTAR study, which evaluated its CoStar paclitaxel-eluting stent. The trial also will evaluate a reduced duration of anti-platelet therapy following stent implantation. Conor expects to complete enrollment for the RAPID study in the second half of this year, with initial results available in 2007. The firm also plans to test a drug-eluting stent that combines pimecrolius and paclitaxel (1"The Gray Sheet" Feb. 20, 2006, p. 7)...
You may also be interested in...
Conor CoStar Cleared For European Launch; Firm Modifies U.S. Trial Design
Conor Medsystems will launch its CoStar paclitaxel-eluting, cobalt-chromium coronary stent in Europe, having just received a CE mark, the firm said Feb. 17
Interview: Theradaptive To Enter Clinical Trial For Spinal Fusion Gel
Theradaptive, which makes a device-biologic combination product to help speed bone healing, recently got authorization to start human trials from the US FDA. Medtech Insight spoke to CEO Luis Alvarez about the company’s past, present and future.
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.